



Tuberculosis and Non-tuberculous Mycobacterial Infections: Control, Diagnosis and Antimicrobial Therapies

Guest Editor:

Dr. Matt D. Johansen

Centre for Inflammation,
Centenary Institute & University
of Technology Sydney,
Missenden Rd, Camperdown,
NSW 2050, Australia

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

Dear Colleagues,

It is estimated that approximately 1 billion people are currently infected with *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB). Moreover, the incidence of infections with non-tuberculous mycobacteria (NTM) is exponentially increasing, frequently surpassing new TB infections in developed countries. Collectively, TB and NTM infections represent a significant global healthcare crisis which is further exacerbated by the increased emergence of multidrug resistance and the lack of novel therapies.

In this Special Issue of *Antibiotics*, we are seeking original research articles, short communications, reviews, case reports, and perspectives that cover but are not limited to the following topics:

- Control measures to combat TB and NTM infections;
- Diagnosis for the identification of TB and NTM infection;
- Novel antimicrobial therapies and new therapeutic drug targets;
- Mechanisms of antimicrobial resistance in TB and NTM species;
- New cellular and animal models to examine the efficacy of antimicrobial therapies against TB and NTM infections.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)